| A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. |
- TRIAL ID | NTR2477 |
| - ACRONYM | HOVON 103 AML Tosedostat |
 |
| Rituximab in Primary Central Nervous system Lymphoma.
A randomized HOVON / ALLG intergroup study.
|
- TRIAL ID | NTR2427 |
| - ACRONYM | HOVON 105 PCNSL |
|
| A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. |
- TRIAL ID | NTR2294 |
| - ACRONYM | HOVON 103 AML Lenalidomide |
|
| Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS =>1.5). |
- TRIAL ID | NTR2187 |
| - ACRONYM | HOVON 102 AML |
|
| Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77). |
- TRIAL ID | NTR2086 |
| - ACRONYM | HOVON 77 NHL |
|
| Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. |
- TRIAL ID | NTR2004 |
| - ACRONYM | HOVON 100 ALL |
|
| Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation. |
- TRIAL ID | NTR1757 |
| - ACRONYM | HOVON 80 NHL |
|
| Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS >= 1.5) |
- TRIAL ID | NTR1446 |
| - ACRONYM | HOVON 92 AML |
|
| RNA-DC vaccination in multiple myeloma. |
- TRIAL ID | NTR1086 |
| - ACRONYM | N/A |
|
| A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years. |
- TRIAL ID | NTR904 |
| - ACRONYM | HOVON 81 AML |
|
| Anti-CD20 therapy for the treatment of
chronic graft versus host disease.
|
- TRIAL ID | NTR709 |
| - ACRONYM | R'mabcGVHD |
|
| Dutch Belgian randomised lung cancer screening trial (NELSON). |
- TRIAL ID | NTR636 |
| - ACRONYM | NELSON |
|
| Simply Capecitabine in rectal cancer after irradiation plus TME. |
- TRIAL ID | NTR552 |
| - ACRONYM | SCRIPT |
|
| PORTEC-2: Postoperative Radiation Therapy for Endometrial Carcinoma – a multicenter randomised phase III trial comparing external beam radiation and vaginal brachytherapy. |
- TRIAL ID | NTR332 |
| - ACRONYM | PORTEC-2 |
|
| Postoperative Accelerated RadioTherapy versus conventional radiotherapy in squamous cell head and neck cancer (POPART). A phase III randomised study. |
- TRIAL ID | NTR310 |
| - ACRONYM | POPART, CKTO 2003-11 |
|
| Microarray Analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens, a randomized phase III study. |
- TRIAL ID | NTR286 |
| - ACRONYM | MATADOR, BOOG 2005-02, CKTO 2004-04 |
|
| The effect of comprehensive counseling by a nurse specialist on depressive symptoms and quality of life:
A prospective randomized study in patients with head and neck cancer.
|
- TRIAL ID | NTR257 |
| - ACRONYM | NUCAI |
|
| Intensified CHOP of 12-weeks duration plus G-CSF as compared with standard CHOP of 24-weeks duration for patients with intermediate-prognosis Non Hodgkin’s Lymphoma. |
- TRIAL ID | NTR239 |
| - ACRONYM | HOVON 26 NHL |
|
| A randomized phase III study on the effect of Thalidomide combined with Adriamycin, Dexamethasone (AD) and High Dose Melphalan in patients with multiple myeloma. |
- TRIAL ID | NTR238 |
| - ACRONYM | HOVON 50 MM / GMMG-HD3 |
|
| A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study. |
- TRIAL ID | NTR233 |
| - ACRONYM | HOVON 50 MM |
|
| Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone. |
- TRIAL ID | NTR232 |
| - ACRONYM | HOVON 49 MM |
|
| Randomized induction and post induction therapy in adult patients (<= 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score >= 1.5. |
- TRIAL ID | NTR230 |
| - ACRONYM | HOVON/SAKK 42 AML |
|
| Early intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study. |
- TRIAL ID | NTR228 |
| - ACRONYM | HOVON 37 ALL |
|
| A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance in patients with multiple myeloma. |
- TRIAL ID | NTR213 |
| - ACRONYM | HOVON 65 MM / GMMG-HD4 |
|
| Randomized induction and post induction therapy in older patients (>= 61 yrs of age) with acute myelocytic leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). |
- TRIAL ID | NTR212 |
| - ACRONYM | HOVON 43 AML / SAKK 30/01 |
|
| A randomized phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (MabThera) during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapsed or progressive B-cell non-Hodgkin’s lymphoma. |
- TRIAL ID | NTR188 |
| - ACRONYM | HOVON 44 NHL |
|
| European Randomized Study of Screening for Prostate Cancer. |
- TRIAL ID | NTR156 |
| - ACRONYM | ERSPC |
|
